Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists

A method of treating a subject with a uveitis therapeutic agent, wherein the subject has B27-negative uveitis, the method comprising:

• determining whether the subject has an Inositol Polyphosphate Multikinase (IPMK) variant nucleic acid molecule or an Indoleamine 2,3-dioxygenase 2 (IDO2) variant nucleic acid molecule by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the IPMK variant nucleic acid molecule and/or the IDO2 variant nucleic acid molecule;
• and
• administering or continuing to administer the uveitis therapeutic agent in a standard dosage amount to a subject that is IPMK reference and IDO2 reference;
• administering or continuing to administer the uveitis therapeutic agent in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous or homozygous for the IPMK variant nucleic acid molecule, and/or administering an IPMK therapeutic agent to the subject;
• and
• administering or continuing to administer the uveitis therapeutic agent in an amount that is the same as or less than a standard dosage amount to a subject that is heterozygous or homozygous for the IDO2 variant nucleic acid molecule, and/or administering an IDO2 agonist to the subject;
• wherein the presence of a genotype having the IPMK variant nucleic acid molecule and/or the IDO2 variant nucleic acid molecule indicates the subject has an increased risk of developing uveitis.